Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2023.
Source: fool.com
Page 21 - Michael Yee News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Yee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Yee Today - Breaking & Trending Today
Eisai expects Alzheimer's drug to rake in revenue of $66.5 mln by March
Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen from its recently approved Alzheimer's drug, Leqembi, by March 2024. The company said...
Source: marketscreener.com
Biogen Reports Earnings Wednesday. Here's What to Expect.
When Biogen reports earnings Wednesday, investors won’t be paying much attention to the numbers. Biogen is in a period of cost-cutting, and trying to build...
Source: marketwatch.com
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March
(Reuters) - Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's...
Source: kelo.com
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March
Jefferies analyst Michael Yee said the Leqembi patient target given by Eisai was "very achievable" and estimated the drug to generate revenue of $28 million in 2023. The drugmaker said the number of neurologists and Alzheimer's disease specialists who were willing to prescribe Leqembi jumped to 2,500 in October from 1,400 in June. Eisai, which has a 50:50 profit and loss sharing agreement for Leqembi globally with Biogen, has the final decision-making authority.
Source: yahoo.com